A cross-sectional analysis of mifepristone, misoprostol, and combination mifepristone-misoprostol package inserts obtained in 20 countries.
Abortifacient Agents
/ adverse effects
Abortion, Induced
/ adverse effects
Alprostadil
/ analogs & derivatives
Cross-Sectional Studies
Developing Countries
Drug Therapy, Combination
Female
Humans
Mifepristone
/ adverse effects
Misoprostol
/ adverse effects
Pregnancy
Pregnancy Trimester, First
Product Labeling
/ methods
Treatment Outcome
Abortion
Medical abortion
Mifepristone
Misoprostol
Package insert
Journal
Contraception
ISSN: 1879-0518
Titre abrégé: Contraception
Pays: United States
ID NLM: 0234361
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
08
11
2019
revised:
09
01
2020
accepted:
20
01
2020
pubmed:
8
2
2020
medline:
20
7
2021
entrez:
8
2
2020
Statut:
ppublish
Résumé
To evaluate the characteristics, clinical information, and storage instructions contained in package inserts from medical abortion commodities collected in low- and middle-income countries. From November 2017 to February 2018 mifepristone, misoprostol, and combined mifepristone-misoprostol (combipack) products were collected to populate the Medical Abortion Commodities Database. We extracted stated indications for use, storage instructions, and date of last revision from each package insert obtained. For those inserts listing medical abortion as an indication, we also extracted eligibility criteria, recommended regimens, side effects, and contraindications. We identified 41 package inserts from 20 countries; 19 (46%) listed medical abortion as an indication including all 7 combipacks, all 7 mifepristone products, and 5/27 (19%) misoprostol products. Date of last insert revision ranged from 1991 to 2016. Gestational age limits for early medical abortion ranged from 49 days to "first trimester." Three (43%) mifepristone products recommended a 600 mg oral dose and two (29%) recommended regimens with gemeprost. Eighteen (67%) misoprostol and one (14%) combipack inserts recommended protection from moisture. The characteristics, clinical information, and storage instructions in medical abortion product package inserts from a variety of field settings in low- and middle-income countries included inadequate storage instructions and outdated gestational age limits and regimens. There is an urgent need to revisit approved inserts for medical abortion products in low- and middle-income countries to ensure information is accurate and reflects the current evidence base. Simultaneously, providing supplemental instructions targeted at users may fill some gaps. People have a right to accurate information to ensure a safe and effective medical abortion experience.
Identifiants
pubmed: 32032639
pii: S0010-7824(20)30030-5
doi: 10.1016/j.contraception.2020.01.011
pii:
doi:
Substances chimiques
Abortifacient Agents
0
Misoprostol
0E43V0BB57
Mifepristone
320T6RNW1F
gemeprost
45KZB1FOLS
Alprostadil
F5TD010360
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
315-320Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.